MTarget Selects iBASIS to Introduce CPaaS Mobile Marketing Campaigns via APIs
10.5.2022 08:00:00 EEST | Business Wire | Press release
iBASIS, the leading provider of communications solutions for operators and digital players worldwide, announced that MTarget, a French B2B direct marketing services provider specialized in mobile solutions, has selected iBASIS to deploy campaign management via programmable voice calls for call centers and businesses in banking, finance, and retail.
Business customers will benefit from a flexible and cost-efficient CPaaS solution that uses voice services for their marketing campaigns, security via multi-factor authentication, notifications, and customer services. The easy and quick customization of defined voice messages through APIs will help them reach an identified group of users in a limited period of time. The cloud-based, ready-to-deploy voice CPaaS solution is a very cost-efficient channel to market with no upfront CapEx investment or commitments required. The purely consumption-based pricing structure allows service providers to be more flexible and create their own commercial models.
“The iBASIS Network and their cloud-based portfolio is a perfect fit for us as they combine global coverage, scale, and technology innovation. Our direct marketing campaigns require high quality and capacity (up to 10,000 simultaneous calls) and iBASIS demonstrated and delivered both. By integrating their carrier channel reach, we are unlocking the potential for a new range of direct marketing campaigns in regions of the world where voice remains the most efficient communication tool,” said Stéphane Faugeras, President, MTarget.
The CPaaS estimated market size was 4-8 billion USD in 2021, with CAGR of 35-57 percent. Along with messaging, programmable voice communications, which covers voice and telephony services, is one of the largest segments estimated at 3.2 billion USD in 2021 by IDC.
“We are delighted to work with MTarget and their operations teams who are extremely focused on quality of services, customer engagement, and innovation. MTarget offers a very high performing CPaaS solution for businesses that want to launch cost-effective promotional or communication campaigns to their end users via programmable voice,” said Guillaume Klein, VP, Product Management at iBASIS.
By leveraging iBASIS’ carrier-grade network and its extensive connections with mobile operators worldwide, marketing campaigns are immediately tailored based on capacity and coverage. Enterprise customers can take advantage of end-to-end visibility while monitoring their mobile campaigns with full call tracking analytics. Enterprises can measure the effectiveness of sales and marketing campaigns, brand messaging, and advertising while keeping control over their customer engagement process.
At International Telecoms Week (ITW), May 9-12, iBASIS will present its cloud communications and CPaaS offering. Visit us at booth 411.
* IDC: Market Analysis Perspective : Worldwide Communications Platform as a Service, 2021
ABOUT iBASIS
iBASIS is the leading communications solutions provider enabling operators and digital players worldwide to perform and transform. Powered by Tofane Global, iBASIS is the first independent communications specialist, ranking third largest global wholesale voice operator, Top 3 LTE IPX vendor with 700+ LTE destinations, and a leading Carrier Cloud Communications player and IoT solution provider. iBASIS provides the end-to-end Global Access for Things™ connectivity solution, delivering single source cellular IoT access (LTE, LTE-M and NB-IoT) worldwide provisioned through GSMA-standard eSIM/eUICC technology. iBASIS today serves 1,000+ customers across 18 offices worldwide. For more information, please visit iBASIS.com.
ABOUT MTARGET
MTarget, a telecom operator and expert in mobile solutions since 2006, designs personalized, ready-to-use communication solutions: SMS, rich SMS, location-based SMS, email, voice and customer acquisition. MTarget's technological expertise and market experience allow it to constantly innovate in order to offer new customer experiences, pilot projects and recommendations adapted to its partners. Over the years, MTarget has developed a strong international presence through various activities in Europe and Africa. For more information, please visit mtarget.fr.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005038/en/
Contact information
Media
iBASIS
Melissa Coffman
26FIVE Tech Lab
+1 202.251.1793
iBASIS@26FIVE.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
REPLY: The Board of Directors Approves the Quarterly Report Dated 31 March 202615.5.2026 14:38:00 EEST | Press release
Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2026. Since the beginning of the year, the Group has recorded a consolidated revenues amounting to €645.0 million, an increase of 6.2% compared to the corresponding data for 2025. All indicators are positive for the period. In the first quarter of 2026 the consolidated EBITDA stood at €112.0 million compared to €105.3 million in 2025, equal to 17.4% of the turnover. EBIT, from January to March, was €95.1 million (€88.7 million in 2025) and is equal to 14.7% of the turnover. The profit before tax, from January to March, was €99.8 million (€86.9 million in 2025), equal to 15.5% of the turnover. The net financial position of the Group on 31 March 2026 is positive at €643 million. The net financial position on 31 December 2025 was positive for €467.6 million. “The results we have presented - said Mario Rizzante, Chairman of Reply - confirm the soundness of the path we have undertaken in recen
Organon to Present New Research on Access and Value at ISPOR 202615.5.2026 14:30:00 EEST | Press release
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Across 8 accepted abstracts, the data reflect Organon’s commitment to generating real-world evidence—rooted in lived experiences—that can help inform healthcare decision-making and improve health outcomes across a range of therapeutic areas. “Health economics and outcomes research is critical to ensuring the right treatments reach patients and that health systems can sustain this approach over time,” said Juan Camilo Arjona Ferreira, MD, Head of R&D and Chief Medical Officer at Organon. “At ISPOR 2026, Organon
SES Announces Extraordinary General Meeting of Shareholders15.5.2026 09:30:00 EEST | Press release
SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Extraordinary General Meeting of SES, Société Anonyme, to be held at the Company's registered office at Château de Betzdorf, L-6815 Betzdorf (the "Company"), Luxembourg, on Wednesday 17 June 2026 at 3:00 p.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Cancellation of shares purchased in connection with the buy-back programme of 2 November 2023, as amended on 2 May 2024, in accordance therewith and pursuant thereto - Reduction of the share capital in accordance with article 450-5 of the law of 10 August 1915 on commercial companies, as amended, by forty-four million nine hundred ten thousand seven hundred eighty euro (EUR 44,910,780) through the cancellation of thirty-five million nine hundred and twenty-eight thousand six hundred and twenty-four (35,928,624) shares divided into (i) twenty-three million nine hundred and fifty-two thousand four hun
Experian Partners With ServiceNow to Scale Trusted Decisioning to Agentic AI15.5.2026 09:00:00 EEST | Press release
Experian, the global data and technology company, and ServiceNow (NYSE: NOW), the AI control tower for business reinvention, today unveil a new global multi-year partnership which harnesses the power of autonomous AI agents across platforms, helping businesses make faster and smarter decisions at scale. Through this partnership, autonomous AI agents can gain the ability to act faster, and more consistently, starting with employee onboarding, third-party risk management and model life cycle governance use cases. A major challenge for global organisations adopting agentic AI is achieving scale, with deployments often constrained by a lack of trusted data. In fact, industry research shows that data limitations are the primary barrier for eight in ten organisations. By connecting trusted intelligence directly into enterprise workflows, this partnership enables agentic AI to scale well beyond pilot deployments. With the Experian Ascend Platform natively connected to the ServiceNow AI Platfo
Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet15.5.2026 04:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that the results of the Integral-1 study, one of two global Phase III clinical trials evaluating the efficacy and safety of its novel β-lactamase inhibitor nacubactam (development code: OP0595), have been published in The Lancet. The article is entitled “---Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial” (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00596-9/fulltext) Integral-1 is a global, double-blind, randomized Phase III trial (jRCT2031230075) in patients with complicated urinary tract infection or acute uncomplicated pyelonephritis that compared the efficacy and safety of nacubactam co-administered with either cefepime or aztreonam versus imipenem-c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom